A pan-cancer analysis of the microbiome in metastatic cancer
2024 · Cell · 162 citations
https://doi.org/10.1016/j.cell.2024.03.021
B
Birgit S. Geurts
Oncode Institute(NL)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
93
Papers
590
Citations
7
h-index
7
i10-index
Birgit S. Geurts is an academic researcher from Oncode Institute. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Health Systems, Economic Evaluations, Quality of Life & Colorectal Cancer Treatments and Studies. The author has an h-index of 7, co-authored 80 publications.
ORCID: 0009-0007-7205-0890Papers by this author
worksCemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol
2024 · The Lancet Regional Health - Europe · 26 citations
https://doi.org/10.1016/j.lanepe.2024.100875
Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP)
2024 · European Journal of Cancer · 14 citations
https://doi.org/10.1016/j.ejca.2024.113988
Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours
2023 · BMC Cancer · 12 citations
https://doi.org/10.1186/s12885-023-10663-2
Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy
2024 · The Journal of Pathology · 5 citations
https://doi.org/10.1002/path.6279
The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol
2024 · Clinical Cancer Research · 4 citations
https://doi.org/10.1158/1078-0432.ccr-24-0480
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat